Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Identifieur interne : 000921 ( Ncbi/Checkpoint ); précédent : 000920; suivant : 000922Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Auteurs : Brad A. Racette [États-Unis] ; Mikula Stambuk ; Joel S. PerlmutterSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Botulinum Toxins, Type A.
- drug effects : Blinking.
- drug therapy : Blepharospasm.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- Female, Humans, Middle Aged, Treatment Outcome.
Abstract
We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.
DOI: 10.1002/mds.10209
PubMed: 12360571
Affiliations:
- États-Unis
- Missouri (État)
- Saint-Louis (Missouri)
- École de médecine (Université Washington de Saint-Louis)
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003930
- to stream PubMed, to step Curation: 003930
- to stream PubMed, to step Checkpoint: 003942
- to stream Ncbi, to step Merge: 000921
- to stream Ncbi, to step Curation: 000921
Links to Exploration step
pubmed:12360571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName><placeName><settlement type="city">Saint-Louis (Missouri)</settlement><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name></author><author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12360571</idno><idno type="pmid">12360571</idno><idno type="doi">10.1002/mds.10209</idno><idno type="wicri:Area/PubMed/Corpus">003930</idno><idno type="wicri:Area/PubMed/Curation">003930</idno><idno type="wicri:Area/PubMed/Checkpoint">003942</idno><idno type="wicri:Area/Ncbi/Merge">000921</idno><idno type="wicri:Area/Ncbi/Curation">000921</idno><idno type="wicri:Area/Ncbi/Checkpoint">000921</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName><placeName><settlement type="city">Saint-Louis (Missouri)</settlement><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name></author><author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm (drug therapy)</term><term>Blinking (drug effects)</term><term>Botulinum Toxins, Type A (pharmacology)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Missouri (État)</li></region><settlement><li>Saint-Louis (Missouri)</li></settlement><orgName><li>École de médecine (Université Washington de Saint-Louis)</li></orgName></list><tree><noCountry><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name></noCountry><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:12360571
|texte= Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:12360571" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |